Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

392
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
392
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

721
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
721
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced circulating FABP2 in patients with moderate to severe COVID-19 may indicate enterocyte functional change rather than cell death.

Scientific reports·2022
Same author

Lombardy diagnostic and therapeutic network of thrombotic microangiopathy.

Orphanet journal of rare diseases·2022
Same author

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

ESMO open·2022
Same author

Evaluation of procoagulant imbalance in Cushing's syndrome after short- and long-term remission of disease.

Journal of endocrinological investigation·2021
Same author

Evolution of Haemophilia Care in Europe: 10 years of the principles of care.

Orphanet journal of rare diseases·2020
Same author

COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020

Related Experiment Video

Updated: Apr 12, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Long-term prophylaxis in severe factor VII deficiency.

S M Siboni1, E Biguzzi1, C Mistretta1

  • 1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Dipartimento delle Units Multispecialistiche e dei Trapianti, Unità Operativa Complessa di Ematologia non Tumorale e Coagulopatie, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|May 9, 2015
PubMed
Summary
This summary is machine-generated.

Prophylaxis is effective for severe Factor VII (FVII) deficiency, particularly for CNS and GI bleeding, and hemarthrosis. Tailored doses of FVII concentrate or recombinant FVIIa can prevent severe bleeding events.

Keywords:
factor VII deficiencylong-term prophylaxisrare coagulation disorders

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Related Experiment Videos

Last Updated: Apr 12, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Area of Science:

  • Hematology
  • Genetics
  • Pharmacology

Background:

  • Factor VII (FVII) deficiency presents a variable bleeding spectrum, with FVII levels and mutations poorly correlating with bleeding risk.
  • Long-term prophylaxis is crucial for preventing severe bleeding, including CNS events, gastrointestinal bleeding, and hemarthrosis, yet evidence remains limited.
  • Clinical decisions for FVII prophylaxis often lack robust evidence, necessitating further research and data compilation.

Observation:

  • A review of literature and personal experience with three severe FVII deficiency patients was conducted.
  • The primary indications for long-term prophylaxis included CNS bleeding (58%), hemarthrosis (15%), and GI bleeding (9%).
  • Patients received varied dosages and frequencies of prophylactic treatment.

Findings:

  • Prophylactic treatment with 10-30 U/kg of plasma-derived FVII (pdFVII) or 20-30 mcg/kg of recombinant FVIIa (rFVIIa), administered two to three times weekly, demonstrated effectiveness.
  • Prophylaxis is a viable option for severe FVII deficiency patients with a severe bleeding phenotype.
  • Dosing and frequency can be individualized based on patient monitoring and clinical outcomes.

Implications:

  • Monitoring joint conditions for early arthropathy is recommended to guide secondary prophylaxis in FVII deficiency patients.
  • Further research is needed to establish evidence-based guidelines for FVII prophylaxis.
  • Individualized prophylaxis strategies can improve outcomes for patients with severe FVII deficiency and significant bleeding symptoms.